Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds

12-Jul-2011 - Vantia Therapeutics announced it has raised £4 million ($6.5 million) in a series B round. The round was co-led by Novo A/S and SV Life Sciences, and included MVM Life Science Partners, all existing investors in Vantia. The funds have been raised to advance the development of Vantia’s two ...

Vantia Therapeutics appoints Andrew Crockett as Chief Executive Officer

10-Jun-2010 - Vantia Therapeutics announced that it has appointed Andrew Crockett to the position of Chief Executive Officer (CEO). Since joining Vantia in 2009 as Vice President of Business Development, Mr Crockett has made a significant contribution to Vantia’s corporate development. Mr Crockett was ...

Vantia Therapeutics reveals structure of its novel small molecule treatment for dysmenorrhoea, VA111913

30-Mar-2010 - Vantia Therapeutics announced that it revealed the structure of drug candidate VA111913 for the first time at the American Chemical Society’s (ACS) National Meeting in San Francisco, USA. The structure was presented as part of an oral session at the meeting and also chosen by ACS to be ...

Vantia Therapeutics’ lead candidate VA106483 enters Phase IIb trial for nocturia

04-Feb-2010 - Vantia Therapeutics announced it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia. The study is a randomised, double-blind, placebo-controlled study and is expected to recruit approximately 120 male patients at 20 centres in the US. The study will ...

Vantia Therapeutics’ VA111913 Enters Phase II Proof-of-Concept Trials for Dysmenorrhoea

08-Oct-2009 - Vantia Therapeutics announced that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered Phase II proof-of-concept trials. In addition, Vantia announces results of the successful Phase I trial of VA111913, which showed the product candidate to be ...

Vantia Therapeutics Appoints Andrew Crockett as Vice President Business Development

28-Aug-2009 - Vantia Therapeutics announced the appointment of Andrew Crockett as Vice President Business Development. Andrew joins Vantia from the US specialty pharma company ZARS Pharma where he was most recently Vice President Business Development. During his career he has identified, negotiated and ...

Vantia Therapeutics’ lead candidate VA106483 demonstrates positive anti-diuretic effect in Phase IIa trial in nocturia

30-Jun-2009 - Vantia Therapeutics announced positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased ...

Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs

23-Apr-2009 - Vantia Therapeutics announced the appointment of Rachel Morten as Head of Regulatory Affairs. Rachel has more than 24 years experience in global regulatory affairs and product development in the pharmaceutical and animal health industries. Most recently an independent regulatory affairs ...

Vantia Therapeutics’ pipeline continues to mature

VA106483 completes Phase IIa trial and VA111913 completes Phase I dosing

26-Mar-2009 - Vantia Therapeutics announced further clinical trial progress with its two lead development compounds, VA106483 for nocturia associated with benign prostatic hypertrophy (BPH) and VA111913 for dysmenorrhoea. The Phase IIa trial of VA106483 has completed, while dosing is complete in the Phase I ...